Describe the role of biomarker profiling, including alterations involving the MET pathway, in guiding treatment decisions for patients with advanced non-squamous non-small cell lung cancer (NSCLC).

Summarize key efficacy and safety findings from a Phase 2 NSCLC trial.

Discuss a treatment option for adult patients with previously-treated, locally advanced, or metastatic non-squamous NSCLC.